Tuesday, September 04, 2012 7:31:49 AM
http://ir.codexis.com/phoenix.zhtml?c=208899&p=irol-newsArticle&ID=1730924&highlight=
... " Under the New Agreement, which is effective August 31, 2012, Shell has granted Codexis a royalty-bearing, non-exclusive license to develop, manufacture, use and sell cellulase enzymes developed under the companies’ Amended and Restated Collaborative Research Agreement, effective November 1, 2006 (the “Shell Research Agreement”). The scope of the New Agreement is worldwide, except Brazil, for enzymes used in the biofuels field. Codexis already has exclusive rights to commercialize its cellulase enzymes in other fields.
“Codexis has developed some of the most cost effective and competitively advantaged cellulase enzymes in the world. Securing the rights to market these enzymes to advanced biofuel companies outside of Shell is a major milestone for the company,” said John Nicols, President and CEO of Codexis. “We also remain focused on the Brazil market, where our discussions with Raízen continue regarding commercialization of our cellulase enzymes for second generation ethanol production.”
In exchange for these new rights, Codexis will be obligated to pay Shell a low single-digit percentage royalty on net sales of CodeXymeTM cellulase enzymes to customers other than Shell and its affiliates. Codexis will also be obligated to pay Shell a low single-digit percentage royalty on Codexis’ own use of cellulase enzymes in the biofuels field. Shell is also entitled to preferential pricing on purchases of cellulase enzymes from Codexis should the companies mutually agree to enter into a future supply arrangement." ...
Recent CDXS News
- Codexis Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/02/2024 08:05:00 PM
- Codexis to Report First Quarter 2024 Financial Results on May 2 • GlobeNewswire Inc. • 04/18/2024 08:05:10 PM
- Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board • GlobeNewswire Inc. • 04/11/2024 11:05:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:02:33 PM
- Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 02/28/2024 09:05:00 PM
- Biotech Rallied Strongly On Exclusive Licensing Agreement • AllPennyStocks.com • 02/27/2024 05:15:00 PM
- Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche • GlobeNewswire Inc. • 02/26/2024 09:05:42 PM
- Codexis to Participate in TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/26/2024 01:05:47 PM
- Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board • GlobeNewswire Inc. • 02/20/2024 01:05:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:01:01 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:51:41 PM
- Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28 • GlobeNewswire Inc. • 02/14/2024 09:05:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:19:57 PM
- Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones • GlobeNewswire Inc. • 02/13/2024 09:05:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:06:35 PM
- seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting • GlobeNewswire Inc. • 02/01/2024 09:05:07 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/24/2024 07:27:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 01:30:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 02:24:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 02:24:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 02:23:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 02:23:40 AM
- Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108 • GlobeNewswire Inc. • 12/27/2023 01:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 01:30:30 PM
- Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase • GlobeNewswire Inc. • 12/13/2023 09:06:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM